AP2007003959A0 - Cupredoxin derived transport agents and methods ofuse thereof - Google Patents

Cupredoxin derived transport agents and methods ofuse thereof

Info

Publication number
AP2007003959A0
AP2007003959A0 AP2007003959A AP2007003959A AP2007003959A0 AP 2007003959 A0 AP2007003959 A0 AP 2007003959A0 AP 2007003959 A AP2007003959 A AP 2007003959A AP 2007003959 A AP2007003959 A AP 2007003959A AP 2007003959 A0 AP2007003959 A0 AP 2007003959A0
Authority
AP
ARIPO
Prior art keywords
transport agents
cupredoxin derived
derived transport
methods ofuse
ofuse
Prior art date
Application number
AP2007003959A
Other languages
English (en)
Inventor
Ananda Chakrabarty
Original Assignee
Ananda Chakrabarty
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ananda Chakrabarty filed Critical Ananda Chakrabarty
Publication of AP2007003959A0 publication Critical patent/AP2007003959A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/221—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by the targeting agent or modifying agent linked to the acoustically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Acoustics & Sound (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AP2007003959A 2004-10-07 2005-10-06 Cupredoxin derived transport agents and methods ofuse thereof AP2007003959A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61678204P 2004-10-07 2004-10-07
US68050005P 2005-05-13 2005-05-13
US70029705P 2005-07-19 2005-07-19
PCT/US2005/035758 WO2006088508A2 (en) 2004-10-07 2005-10-06 Cupredoxin derived transport agents and methods of use thereof

Publications (1)

Publication Number Publication Date
AP2007003959A0 true AP2007003959A0 (en) 2007-04-30

Family

ID=36916885

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2007003959A AP2007003959A0 (en) 2004-10-07 2005-10-06 Cupredoxin derived transport agents and methods ofuse thereof

Country Status (17)

Country Link
US (5) US7691383B2 (xx)
EP (1) EP1797114A4 (xx)
JP (2) JP2008515428A (xx)
KR (1) KR20070108128A (xx)
CN (1) CN101437842A (xx)
AP (1) AP2007003959A0 (xx)
AU (1) AU2005327535A1 (xx)
BR (1) BRPI0515850A (xx)
CA (1) CA2582164A1 (xx)
CR (1) CR9033A (xx)
EA (1) EA200700813A1 (xx)
IL (1) IL182202A0 (xx)
NO (1) NO20072355L (xx)
TN (1) TNSN07113A1 (xx)
UA (1) UA97466C2 (xx)
WO (1) WO2006088508A2 (xx)
ZA (1) ZA200702855B (xx)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US7618939B2 (en) * 2001-02-15 2009-11-17 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
US7381701B2 (en) 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
US7556810B2 (en) 2005-07-19 2009-07-07 The Board Of Trustees Of The University Of Ilinois Compositions and methods to control angiogenesis with cupredoxins
US7301010B2 (en) * 2001-02-15 2007-11-27 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating HIV infection with cupredoxin and cytochrome c
US9096663B2 (en) * 2001-02-15 2015-08-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
EP1720887B1 (en) * 2004-02-23 2008-04-02 Dow Gloval Technologies Inc. Aqueous-based adhesive for bonding low surface energy substrates
US8158574B2 (en) * 2004-10-07 2012-04-17 Cdg Therapeutics, Inc. Compositions and methods to prevent cancer with cupredoxins
US9968685B2 (en) * 2004-10-07 2018-05-15 Brad N. Taylor Methods to treat cancer with cupredoxins
US20090208476A1 (en) * 2006-05-19 2009-08-20 Tapas Das Gupta Compositions and methods to concurrently treat or prevent multiple diseases with cupredoxins
US9598470B2 (en) * 2004-10-07 2017-03-21 Craig W. Beattie Compositions and methods to prevent cancer by stabilizing P53 through non MDM2-mediated pathways
US9434770B2 (en) * 2004-10-07 2016-09-06 Tapas K Das Gupta Modified cupredoxin derived peptides
US10675326B2 (en) 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
EA200700813A1 (ru) 2004-10-07 2008-10-30 Ананда Чакрабарти Транспортирующие вещества, производные купредоксина и способы их применения
AU2006284490A1 (en) * 2005-07-19 2007-03-01 The Board Of Trustees Of The University Of Illinois Compositions and methods to control angiogenesis with cupredoxins
WO2007012004A2 (en) 2005-07-19 2007-01-25 The Board Of Trustees Of The University Of Illinois Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof
US20100278937A1 (en) * 2005-10-06 2010-11-04 Das Gupta Tapas K Compositions and methods to prevent and/or treat cancer with pa-card
US10266868B2 (en) * 2006-05-19 2019-04-23 The Board Of Trustees Of The University Of Illinois Compositions for treating HIV infection with cupredoxin and cytochrome C
CN101600447A (zh) * 2006-09-11 2009-12-09 伊利诺斯大学理事会 铜氧还蛋白衍生肽类的修饰物及其使用方法
WO2008033987A2 (en) * 2006-09-14 2008-03-20 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
US8017749B2 (en) 2006-12-04 2011-09-13 The Board Of Trustees Of The University Of Illinois Compositions and methods to treat cancer with cupredoxins and CpG rich DNA
EP2117573A4 (en) * 2007-01-11 2011-02-16 Univ Illinois COMPOSITIONS AND METHODS FOR TREATING EPHRIN SIGNALING WITH CUPREDOXINES AND MUTANTS THEREOF
CA2677803A1 (en) * 2007-02-08 2008-08-14 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
BRPI0806029A2 (pt) * 2007-07-19 2009-11-10 Biosigma Sa plasmìdeos para transformação de bactérias do gênero aciditiobacillus spp. e método de transformação
DK2197903T3 (en) * 2007-09-04 2015-01-05 Us Gov Health & Human Serv Deletions in Domain II from Pseudomonas exotoxin A that reduce non-specific TOXICITY
WO2009078977A2 (en) * 2007-12-14 2009-06-25 Cdg Therapeutics Inc Compositions and methods to concurrently treat or prevent multiple diseases with cupredoxins
ES2703363T3 (es) * 2008-02-01 2019-03-08 Massachusetts Gen Hospital Uso de microvesículas en el diagnóstico y pronóstico de tumores cerebrales
US20110171259A1 (en) * 2008-09-05 2011-07-14 Martin Gagne Novel Compositions and Adjuvants
AU2010215858A1 (en) * 2009-02-20 2011-09-22 Cdg Thereapeutics, Inc. Compositions and methods to prevent and/or treat cancer with Pa -CARD
EP3461912B1 (en) 2009-09-09 2022-07-13 The General Hospital Corporation Use of microvesicles in analyzing nucleic acid profiles
EP2475989A4 (en) 2009-09-09 2013-02-27 Gen Hospital Corp USE OF MICROVESICLES IN THE ANALYSIS OF KRAS MUTATIONS
WO2011123795A1 (en) 2010-04-02 2011-10-06 Battelle Memorial Institute Methods for associating or dissociating guest materials with a metal organic framework, systems for associating or dissociating guest materials within a series of metal organic frameworks, and gas separation assemblies
WO2012031008A2 (en) 2010-08-31 2012-03-08 The General Hospital Corporation Cancer-related biological materials in microvesicles
EP2638057B1 (en) 2010-11-10 2019-03-06 Exosome Diagnostics, Inc. Method for isolation of nucleic acid containing particles and extraction of nucleic acids therefrom
US9811152B2 (en) * 2014-01-21 2017-11-07 Osterhout Group, Inc. Eye imaging in head worn computing
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
WO2016176573A1 (en) 2015-04-30 2016-11-03 Board Of Regents, The University Of Texas System Antibacterial polypeptide libraries and methods for screening the same
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827934A (en) 1988-03-08 1998-10-27 The University Of Wyoming Cytotoxic diphtheria toxin fragments
US5972899A (en) 1996-01-25 1999-10-26 New York University Apoptosis induced by Shigella IpaB
JP3715745B2 (ja) * 1997-06-17 2005-11-16 ジーイー横河メディカルシステム株式会社 超音波撮像装置
EP1144605B1 (en) 1999-01-26 2009-12-16 University College London Dimethylarginine dimethylaminohydrolases
US6800437B1 (en) 1999-08-06 2004-10-05 Tibotec Bvba Method of monitoring a biological system by labeling with an apo metal binding protein
US20020164703A1 (en) 2000-12-21 2002-11-07 Krzysztof Pawlowski Card-domain containing polypeptides, encoding nucleic acids, and methods of use
US7338766B2 (en) * 2001-02-15 2008-03-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating malaria with cupredoxin and cytochrome
AU2002311753B2 (en) 2001-02-15 2008-04-03 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US6708054B2 (en) * 2001-04-12 2004-03-16 Koninklijke Philips Electronics, N.V. MR-based real-time radiation therapy oncology simulator
JP4091318B2 (ja) * 2002-03-04 2008-05-28 ジーイー・メディカル・システムズ・グローバル・テクノロジー・カンパニー・エルエルシー Ｘ線ｃｔ装置
GB0211295D0 (en) 2002-05-16 2002-06-26 Univ London Treatment of pain
MXPA04011451A (es) 2002-05-20 2005-08-15 Chemstop Pty Ltd Procedimiento para la preparacion y activacion de sustancias y un medio para su produccion.
CA2506318C (en) 2002-11-15 2011-07-12 Chiron Srl Unexpected surface proteins in neisseria meningitidis
EA200700813A1 (ru) 2004-10-07 2008-10-30 Ананда Чакрабарти Транспортирующие вещества, производные купредоксина и способы их применения
US7322469B2 (en) 2005-02-17 2008-01-29 International Paper Company Container for recording media
MX2007014598A (es) 2005-05-20 2008-02-07 Univ Illinois Composiciones y metodos para tratar condiciones relacionadas con senalizacion de efrina con cupredoxinas.
CN101600447A (zh) 2006-09-11 2009-12-09 伊利诺斯大学理事会 铜氧还蛋白衍生肽类的修饰物及其使用方法
WO2008033987A2 (en) 2006-09-14 2008-03-20 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
US8017749B2 (en) * 2006-12-04 2011-09-13 The Board Of Trustees Of The University Of Illinois Compositions and methods to treat cancer with cupredoxins and CpG rich DNA
CA2677803A1 (en) 2007-02-08 2008-08-14 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
WO2009078977A2 (en) 2007-12-14 2009-06-25 Cdg Therapeutics Inc Compositions and methods to concurrently treat or prevent multiple diseases with cupredoxins

Also Published As

Publication number Publication date
UA97466C2 (ru) 2012-02-27
EP1797114A2 (en) 2007-06-20
JP2014204720A (ja) 2014-10-30
US8530635B2 (en) 2013-09-10
EP1797114A4 (en) 2009-07-15
EA200700813A1 (ru) 2008-10-30
US20160031947A1 (en) 2016-02-04
US20060149037A1 (en) 2006-07-06
TNSN07113A1 (en) 2008-06-02
IL182202A0 (en) 2007-07-24
CN101437842A (zh) 2009-05-20
US8206685B2 (en) 2012-06-26
CA2582164A1 (en) 2006-08-24
US10239920B2 (en) 2019-03-26
BRPI0515850A (pt) 2008-08-12
JP2008515428A (ja) 2008-05-15
US20140037554A1 (en) 2014-02-06
CR9033A (es) 2010-04-08
AU2005327535A1 (en) 2006-08-24
US7691383B2 (en) 2010-04-06
WO2006088508A3 (en) 2008-12-24
US20100209355A1 (en) 2010-08-19
WO2006088508A2 (en) 2006-08-24
US20130011338A1 (en) 2013-01-10
US9161989B2 (en) 2015-10-20
KR20070108128A (ko) 2007-11-08
ZA200702855B (en) 2008-10-29
NO20072355L (no) 2007-07-04

Similar Documents

Publication Publication Date Title
AP2007003959A0 (en) Cupredoxin derived transport agents and methods ofuse thereof
EP1802588A4 (en) SUBSTITUTED AMINOPYRIMIDONE AND APPLICATIONS THEREOF
IL184308A0 (en) Systems and methods for providing
ZA200701820B (en) Substituted phenylaminothiazoles and use thereof
EP1824467A4 (en) APOGOSSYPOLON AND ITS USES
IL179497A0 (en) Carboranylporphyrins and uses thereof
EP1737565A4 (en) COS CLAUS CONFIGURATIONS AND METHODS
IL184062A0 (en) Visco-supplement composition and methods
IL180365A0 (en) Carboranylporphyrins and uses thereof
EP1761256A4 (en) CLA-ENRICHED MILK FAT AND USE THEREOF
EP1838163A4 (en) MILK PRODUCT COMPONENT - MANUFACTURE AND USE
GB0404694D0 (en) Dolly and transportation using same
EP1786415A4 (en) METABOLISM MODULATION AGENTS AND USES THEREOF
EP1810976A4 (en) BENZONAPHTHACENEGLYCOSIDE DERIVATIVE AND THE USE THEREOF
GB0424552D0 (en) Methods and means
GB0403847D0 (en) Methods and means
ZA200706038B (en) Visco-supplement composition and methods
GB0423275D0 (en) Article and method
GB0421911D0 (en) Methods and means
GB0423658D0 (en) Methods and means
GB0425081D0 (en) Methods and means
GB0419181D0 (en) Methods and means
GB0427483D0 (en) Methods and means
GB0421466D0 (en) Methods and means
IL165458A0 (en) And